Publicaciones (128) Publicaciones de VICTOR NAVAS LOPEZ

2024

  1. Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment

    Biomedicine and Pharmacotherapy, Vol. 173

  2. Genetic and phenotypic findings in 34 novel Spanish patients with DDX3X neurodevelopmental disorder

    Clinical Genetics, Vol. 105, Núm. 2, pp. 140-149

2023

  1. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  2. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  3. Celiac Disease Is a Risk Factor for Mature T and NK Cell Lymphoma: A Mendelian Randomization Study

    International Journal of Molecular Sciences, Vol. 24, Núm. 8

  4. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research

  5. Dietary Habit Modifications in Paediatric Patients after One Year of Treatment with the Crohn’s Disease Exclusion Diet

    Nutrients, Vol. 15, Núm. 3

  6. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis

    Nutrients, Vol. 15, Núm. 19

  7. Impact of the COVID-19 pandemic on the digitization of routine pediatric practice in Spain: A nationwide survey study

    Frontiers in Pediatrics, Vol. 11

  8. Metabolomic Profiling in Children with Celiac Disease: Beyond the Gluten-Free Diet

    Nutrients, Vol. 15, Núm. 13

  9. Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity

    European Journal of Pediatrics, Vol. 182, Núm. 10, pp. 4633-4645

  10. Mitochondrial Stress Links Environmental Triggers with Pro-Inflammatory Signaling in Crohn’s Disease

    Antioxidants, Vol. 12, Núm. 12

  11. Phase angle as a marker of outcome in hospitalized pediatric patients. A systematic review of the evidence (GRADE) with meta-analysis

    Reviews in Endocrine and Metabolic Disorders, Vol. 24, Núm. 4, pp. 751-765

  12. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research, Vol. 194

  13. Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease

    Anales de Pediatria, Vol. 98, Núm. 3, pp. 165-174

  14. Prospective Validation of the LCrossed D sign©mann Index in Children: A Report from the Multicentre Image Kids Study

    Journal of Crohn's and Colitis, Vol. 17, Núm. 6, pp. 943-949

  15. Spanish Pediatricians’ Positions Regarding Prevention, Diagnosis, Nutritional Management, and Challenges in Cow’s Milk Protein Allergy

    Nutrients, Vol. 15, Núm. 16

  16. The Importance of an Early Evaluation after Establishing a Gluten-Free Diet in Children with Celiac Disease

    Nutrients, Vol. 15, Núm. 7

2022

  1. A scale for the identification of the complex chronic pediatric patient (PedCom Scale): A pilot study

    Anales de Pediatria, Vol. 97, Núm. 3, pp. 155-160

  2. Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix

    Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 5, pp. 794-801